FindTrial
Sign In

A clinical multicenter study for the occurrence, development and prognosis of novel coronavirus pneumonia (COVID-19)

A clinical multicenter study on the occurrence, development and prognosis of 2019 ncov infection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030854
Enrollment
Unknown
Registered
2020-03-16
Start date
2020-01-22
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

The triple combination antiviral therapy:abidor,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b)
The dual combination antiviral therapy:,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b)

Sponsors

Li Lanjuan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: From January 22 to February 16, 2020,Patients diagnosed with new coronavirus infection in 15 medical institutions in Zhejiang Province.

Exclusion criteria

Exclusion criteria: Patients with negative detection of new coronavirus nucleic acid

Design outcomes

Primary

MeasureTime frame
white blood cell;lymphocyte;creatinine;CRP;—

Countries

China

Contacts

Public ContactLi Lanjuan

The First Affiliated Hospital, College of Medicine,Zhejiang University

ljli@zju.edu.cn+86 13906514210

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026